Cargando…
The risk factors for cytomegalovirus reactivation following stem cell transplantation
OBJECTIVE: Opportunistic infections like cytomegalovirus (CMV) are among the primary causes of morbidity and mortality in patients undergoing hematipoetic stem cell transplantation (HSCT). This infection is frequently seen in early postengraftment period. So we determined to find the risk factors as...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776549/ https://www.ncbi.nlm.nih.gov/pubmed/26985438 http://dx.doi.org/10.4103/2279-042X.176554 |
_version_ | 1782419161257869312 |
---|---|
author | Valadkhani, Bahareh Kargar, Mona Ashouri, Asieh Hadjibabaie, Molouk Gholami, Kheirollah Ghavamzadeh, Ardeshir |
author_facet | Valadkhani, Bahareh Kargar, Mona Ashouri, Asieh Hadjibabaie, Molouk Gholami, Kheirollah Ghavamzadeh, Ardeshir |
author_sort | Valadkhani, Bahareh |
collection | PubMed |
description | OBJECTIVE: Opportunistic infections like cytomegalovirus (CMV) are among the primary causes of morbidity and mortality in patients undergoing hematipoetic stem cell transplantation (HSCT). This infection is frequently seen in early postengraftment period. So we determined to find the risk factors associated with CMV reactivation. METHODS: We retrospectively evaluated the medical records of 126 consecutive patients who underwent allogenic-HSCT from peripheral blood stem cells from August 2011 to February 2013 in Shariati Hospital. We included HSCT patients with 15 years of age or older, who survived at least 100 days after transplantation. CMV reactivation was detected based on the weekly PP65 assessment. Patients with 10 or more positive cells per 50,000 cells were defined as having high-level antigenemia. FINDINGS: From 126 patients which included in this study, 76 were male (60%). CMV antigenemia was documented in 43 patients (34%). The median time to CMV infection was 40 days (range: 3–77) after transplantation. The incidence of high-level antigenemia during the first 100 days following HSCT was 11%. CONCLUSION: We found that the significant risk factor for CMV antigenemia in multivariate analysis was prior graft-versus-host disease (GVHD) experience and higher donor age. For high-level antigenemia, GVHD or duration of its treatment was significant determinant. |
format | Online Article Text |
id | pubmed-4776549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-47765492016-03-16 The risk factors for cytomegalovirus reactivation following stem cell transplantation Valadkhani, Bahareh Kargar, Mona Ashouri, Asieh Hadjibabaie, Molouk Gholami, Kheirollah Ghavamzadeh, Ardeshir J Res Pharm Pract Clinical Study OBJECTIVE: Opportunistic infections like cytomegalovirus (CMV) are among the primary causes of morbidity and mortality in patients undergoing hematipoetic stem cell transplantation (HSCT). This infection is frequently seen in early postengraftment period. So we determined to find the risk factors associated with CMV reactivation. METHODS: We retrospectively evaluated the medical records of 126 consecutive patients who underwent allogenic-HSCT from peripheral blood stem cells from August 2011 to February 2013 in Shariati Hospital. We included HSCT patients with 15 years of age or older, who survived at least 100 days after transplantation. CMV reactivation was detected based on the weekly PP65 assessment. Patients with 10 or more positive cells per 50,000 cells were defined as having high-level antigenemia. FINDINGS: From 126 patients which included in this study, 76 were male (60%). CMV antigenemia was documented in 43 patients (34%). The median time to CMV infection was 40 days (range: 3–77) after transplantation. The incidence of high-level antigenemia during the first 100 days following HSCT was 11%. CONCLUSION: We found that the significant risk factor for CMV antigenemia in multivariate analysis was prior graft-versus-host disease (GVHD) experience and higher donor age. For high-level antigenemia, GVHD or duration of its treatment was significant determinant. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4776549/ /pubmed/26985438 http://dx.doi.org/10.4103/2279-042X.176554 Text en Copyright: © Journal of Research in Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Clinical Study Valadkhani, Bahareh Kargar, Mona Ashouri, Asieh Hadjibabaie, Molouk Gholami, Kheirollah Ghavamzadeh, Ardeshir The risk factors for cytomegalovirus reactivation following stem cell transplantation |
title | The risk factors for cytomegalovirus reactivation following stem cell transplantation |
title_full | The risk factors for cytomegalovirus reactivation following stem cell transplantation |
title_fullStr | The risk factors for cytomegalovirus reactivation following stem cell transplantation |
title_full_unstemmed | The risk factors for cytomegalovirus reactivation following stem cell transplantation |
title_short | The risk factors for cytomegalovirus reactivation following stem cell transplantation |
title_sort | risk factors for cytomegalovirus reactivation following stem cell transplantation |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776549/ https://www.ncbi.nlm.nih.gov/pubmed/26985438 http://dx.doi.org/10.4103/2279-042X.176554 |
work_keys_str_mv | AT valadkhanibahareh theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation AT kargarmona theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation AT ashouriasieh theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation AT hadjibabaiemolouk theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation AT gholamikheirollah theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation AT ghavamzadehardeshir theriskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation AT valadkhanibahareh riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation AT kargarmona riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation AT ashouriasieh riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation AT hadjibabaiemolouk riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation AT gholamikheirollah riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation AT ghavamzadehardeshir riskfactorsforcytomegalovirusreactivationfollowingstemcelltransplantation |